An Investigational Study to Evaluate Experimental Medication BMS-986165 Compared to Placebo and a Currently Available Treatment in Participants With Moderate-to-Severe Plaque Psoriasis
Purpose
The purpose of this study is to investigate the experimental medication BMS-986165 compared to placebo and a currently available treatment in participants with moderate to severe plaque psoriasis.
Condition
- Psoriasis
Eligibility
- Eligible Ages
- Over 18 Years
- Eligible Genders
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- Plaque psoriasis for at least 6 months - Moderate to severe disease - Candidate for phototherapy or systemic therapy
Exclusion Criteria
- Other forms of psoriasis - History of recent infection - Prior exposure to BMS-986165 or active comparator Other protocol defined inclusion/exclusion criteria could apply
Study Design
- Phase
- Phase 3
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel Assignment
- Primary Purpose
- Treatment
- Masking
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Arm Groups
Arm | Description | Assigned Intervention |
---|---|---|
Experimental BMS-986165 |
BMS-986165 oral administration |
|
Placebo Comparator Placebo |
Placebo oral administration |
|
Active Comparator Active comparator |
Active comparator oral administration |
|
More Details
- Status
- Completed
- Sponsor
- Bristol-Myers Squibb